Tildrakizumab was well tolerated and achieved sustained response in patients with moderate to severe plaque psoriasis of the ...

The following is a summary of “Efficacy and Safety of Tildrakizumab for the Treatment of Moderate-to-Severe Plaque Psoriasis ...

Researchers have established that tildrakizumab, an anti-interleukin-23 p19 antibody, can be used to maintain long-term ...

The FDA has approved Steqeyma® (ustekinumab-stba), a biosimilar to Stelara®, for the treatment of various chronic ...

is highly effective and well tolerated in individuals with moderate to severe plaque psoriasis. Patients receiving the highest dose of 40 mg twice daily achieved 75% clearance, with mild to ...

Medically reviewed by Susan Bard, MD Psoriasis is a skin condition that causes skin to appear scaly and inflamed. It occurs ...

Secukinumab is under clinical development by Novartis and currently in Phase II for Unspecified Dermatological Disorders.

Discover a recent randomised clinical trial that evaluated the efficacy of a new monoclonal antibody to treat plaque ...

China: A new randomized clinical trial has demonstrated that QX004N, a humanized anti-IL-23 monoclonal antibody, offers ...

The following is a summary of “FC01 Higher IL-10+ T-cell and Treg-cell counts in psoriatic skin are associated with ...

Stagnant sales for Bristol Myers Squibb’s Sotyktu have raised questions about whether the tyrosine kinase 2 (TYK2) inhibitor ...

The use of risankizumab after poor response to 2 interleukin-17 inhibitors, secukinumab, and ixekizumab, was safe and effective in plaque psoriasis.